Suicide Gene Therapy (CNS Tumors)

Adv-Mediated HSV-TK/GCV Therapy Promising in Preclinical Testing

Published in Gene Therapy Weekly, September 29th, 1997

Researchers from The Netherlands have pursued in detail the efficacy of adenovirus (Adv)-mediated herpes simplex virus-thymidine kinase (HSV-TK)/Ganciclovir (GCV) suicide gene therapy in preclinical models of central nervous system (CNS) malignancies.

Numerous studies have explored HSV-TK suicide gene therapy in various cancer models, both in vitro and in vivo, using several different vectors and promoters. However, adenoviral-mediated HSV-TK/GCV suicide gene therapy has not been effectively addressed in the literature for human CNS malignancies.

In response to the need to find more effective therapies for CNS malignancies, Arnaud J.P.E. Vincent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-09-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry